D. Tenney

发表

Sequence-dependent Primer Synthesis by the Herpes Simplex Virus Helicase-Primase Complex (*)

R. Hamatake, D. Tenney, A. Sheaffer, 1995, The Journal of Biological Chemistry.

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.

R. Colonno, R. Rose, D. Tenney, 2008, Journal of hepatology.

Inhibition of Hepatitis B Virus Polymerase by Entecavir

Ronald E. Rose, David R. Langley, D. Langley, 2007, Journal of Virology.

Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

P. Angus, N. Warner, S. Locarnini, 2004, Antimicrobial Agents and Chemotherapy.

490 High barrier to resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapy

R. Colonno, R. Rose, D. Tenney, 2006 .

Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection

S. Balsitis, M. Feulner, R. Iyer, 2018, PloS one.

The herpes simplex virus type 1 DNA polymerase accessory protein, UL42, contains a functional protease-resistant domain.

R. Hamatake, M. Cordingley, D. Tenney, 1993, The Journal of general virology.

Entecavir Exhibits Inhibitory Activity against Human Immunodeficiency Virus under Conditions of Reduced Viral Challenge

N. Parkin, M. Krystal, R. Colonno, 2008, Antimicrobial Agents and Chemotherapy.

Entecavir Exhibits Inhibitory Activity against Human Immunodeﬁciency Virus under Conditions of Reduced Viral Challenge (cid:1)

N. Parkin, M. Krystal, R. Colonno, 2008 .

Discovery and Development of Entecavir

N. Meanwell, L. Lehman-Mckeeman, B. Kreter, 2011 .

Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B

K. Tanikawa, N. Hayashi, M. Sata, 2009, Hepatology international.

The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice

P. Ghazal, G. Nilaver, J. Nelson, 1996, Journal of virology.

Developmental analysis of the cytomegalovirus enhancer in transgenic animals

P. Ghazal, G. Ciment, J. Nelson, 1996, Journal of virology.

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations in the C terminus of herpes simplex virus type 1 DNA polymerase can affect binding and stimulation by its accessory protein UL42 without affecting basal polymerase activity

R. Hamatake, M. Cordingley, D. Tenney, 1993, Journal of virology.

Effect of macrophage activation on resistance of mouse peritoneal macrophages to infection with herpes simplex virus types 1 and 2.

J. Rothstein, D. Tenney, P. Morahan, 1988, The Journal of general virology.

Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma Inhibition

R. Hamatake, C. Mazzucco, R. Colonno, 2007, Antimicrobial Agents and Chemotherapy.

Deletions of the carboxy terminus of herpes simplex virus type 1 UL42 define a conserved amino-terminal functional domain

R. Hamatake, M. Cordingley, D. Tenney, 1993, Journal of virology.

Expression of the human cytomegalovirus UL36-38 immediate early region during permissive infection.

D. Tenney, A. Colberg-Poley, D. J. Tenney, 1991, Virology.

Differentiation of the U937 macrophage cell line removes an early block of HSV-1 infection.

D. Tenney, P. Morahan, 1991, Viral immunology.

A functional interaction of ICP8, the herpes simplex virus single-stranded DNA-binding protein, and the helicase-primase complex that is dependent on the presence of the UL8 subunit.

R. Hamatake, D. Tenney, W. Hurlburt, 1997, Journal of General Virology.

A multi‐omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti‐PD1 response in solid tumors

Hao Tang, Namit Kumar, Simon Papillon-Cavanagh, 2022, International journal of cancer.

Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies.

D. Tenney, 2010, Antiviral therapy.

[781] FOUR YEAR ASSESSMENT OF ETV RESISTANCE IN NUCLEOSIDE-NAIVE AND LAMIVUDINE REFRACTORY PATIENTS

A. Cross, C. Baldick, R. Rose, 2007 .

Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present

C. Mazzucco, R. Colonno, A. Walsh, 2006, Antimicrobial Agents and Chemotherapy.

Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase

C. Cianci, R. Colonno, D. Tenney, 1997, Antimicrobial agents and chemotherapy.

Functionalized triazines as potent HCV entry inhibitors.

N. Meanwell, R. Rajamani, M. Kramer, 2017, Bioorganic & medicinal chemistry letters.

The human cytomegalovirus UL98 gene encodes the conserved herpesvirus alkaline nuclease.

D. Tenney, A. Sheaffer, S. Weinheimer, 1997, The Journal of general virology.

Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy

Ronald E. Rose, R. Colonno, R. Rose, 2009, Hepatology.

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

C. Mazzucco, R. Colonno, A. Walsh, 2006, Hepatology.

Herpes Simplex Virus DNA Cleavage and Packaging Proteins Associate with the Procapsid prior to Its Maturation

W. Newcomb, S. Weller, M. Gao, 2001, Journal of Virology.

43 Absence of entecavir resistance emergence in lamivudine-refractory patients treated for at least one year with entecavir in study A1463-014

A. Cross, R. Colonno, R. Hindes, 2004 .

Mechanistic Characterization and Molecular Modeling of Hepatitis B Virus Polymerase Resistance to Entecavir

D. Langley, R. Colonno, A. Walsh, 2010, PloS one.

Entecavir therapy for lamivudine‐refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks

M. Sherman, C. Yurdaydın, Y. Liaw, 2008, Hepatology.

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.

G. Carosi, Ting Chang, D. Shouval, 2009, Journal of hepatology.

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

Ching-Lung Lai, Hui Zhang, U. Iloeje, 2010, Hepatology.

Ultrasensitive Genotypic Detection of Antiviral Resistance in Hepatitis B Virus Clinical Isolates

C. Mazzucco, B. Kienzle, R. Colonno, 2009, Antimicrobial Agents and Chemotherapy.

Entecavir at Five Years Shows Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance

R. Colonno, R. Rose, D. Tenney, 2008 .

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance

C. Mazzucco, R. Colonno, R. Rose, 2008, Hepatology.

Long-term follow-up of entecavir treated protocol-defined non responders in rollover study ETV-901

E. Schiff, M. Sherman, Shou-Dong Lee, 2007 .

W1805 Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in NaïVE Patients

U. Iloeje, R. Rose, D. Tenney, 2009 .

20 ENTECAVIR MAINTAINS A HIGH GENETIC BARRIER TO HBV RESISTANCE THROUGH 6 YEARS IN NAIVE PATIENTS

U. Iloeje, R. Rose, D. Tenney, 2009 .

Human cytomegalovirus US3 and UL36-38 immediate-early proteins regulate gene expression

D. Tenney, P. Benfield, A. Colberg-Poley, 1992, Journal of virology.

Human cytomegalovirus UL36-38 and US3 immediate-early genes: temporally regulated expression of nuclear, cytoplasmic, and polysome-associated transcripts during infection

D. Tenney, A. Colberg-Poley, D. J. TENNEYt, 1991, Journal of virology.

Characterization of monoclonal antibodies recognizing amino- and carboxy-terminal epitopes of the herpes simplex virus UL42 protein.

R. Hamatake, R. Colonno, D. Tenney, 1995, Virus research.

Physical and Functional Interactions between the Herpes Simplex Virus UL15 and UL28 DNA Cleavage and Packaging Proteins

N. Pederson, D. Tenney, A. Sheaffer, 1999, Journal of Virology.

The pseudorabies virus UL28 protein enters the nucleus after coexpression with the herpes simplex virus UL15 protein

N. Pederson, D. Tenney, P. Shaver, 1997, Journal of virology.

A Novel Small Molecule Inhibitor of Hepatitis C Virus Entry

M. Poss, N. Meanwell, C. Mazzucco, 2010, PLoS pathogens.

Characterization of ICP6::lacZ insertion mutants of the UL15 gene of herpes simplex virus type 1 reveals the translation of two proteins

S. Weller, D. Yu, D. Tenney, 1997, Journal of virology.

Evidence for Controlled Incorporation of Herpes Simplex Virus Type 1 UL26 Protease into Capsids

W. Newcomb, S. Weller, M. Gao, 2000, Journal of Virology.

Isolation of Herpes Simplex Virus Procapsids from Cells Infected with a Protease-Deficient Mutant Virus

B. Trus, A. Steven, W. Newcomb, 2000, Journal of Virology.

The UL8 component of the herpes simplex virus helicase-primase complex stimulates primer synthesis by a subassembly of the UL5 and UL52 components.

R. Hamatake, D. Tenney, W. Hurlburt, 1994, The Journal of biological chemistry.

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2021, Clinical Trials.

The human cytomegalovirus US3 immediate-early protein lacking the putative transmembrane domain regulates gene expression.

D. Tenney, A. Colberg-Poley, L. Santomenna, 1993, Nucleic acids research.

Frontline Science: OX40 agonistic antibody reverses immune suppression and improves survival in sepsis

R. Hotchkiss, M. Quigley, A. Walton, 2020, Journal of leukocyte biology.

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.

Daniel K. Wells, J. Wolchok, J. Larkin, 2023, Cancer cell.

High-Throughput Screening and Rapid Inhibitor Triage Using an Infectious Chimeric Hepatitis C Virus

B. Beno, J. Leet, C. Mazzucco, 2012, PloS one.

Effects of differentiation of human macrophage-like U937 cells on intrinsic resistance to herpes simplex virus type 1.

D. Tenney, P. Morahan, 1987, Journal of immunology.

Antibodies to Modulate Surface Receptor Systems Are Often Bivalent and Must Compete in a Two‐Dimensional Cell Contact Region

Yougan Cheng, T. Leil, D. Tenney, 2019, CPT: Pharmacometrics & Systems Pharmacology.

Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).

J. Taube, J. Kirkwood, M. Del Vecchio, 2023, Journal of Clinical Oncology.

RNA analysis and isolation of cDNAs derived from the human cytomegalovirus immediate-early region at 0.24 map units.

D. Tenney, A. Colberg-Poley, 1990, Intervirology.

Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization.

J. Tokarski, N. Meanwell, Scott W. Martin, 2023, ACS medicinal chemistry letters.

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.

G. Carosi, Ting Chang, D. Shouval, 2009, Journal of hepatology.